We are sorry, but NCBI web applications do not support your browser and may not function properly. More information

Results: 4

1.
Fig 1.

Fig 1. From: Estrogen Alone in Postmenopausal Women and Breast Cancer Detection by Means of Mammography and Breast Biopsy.

CONSORT diagram. CEE, conjugated equine estrogen.

Rowan T. Chlebowski, et al. J Clin Oncol. 2010 June 1;28(16):2690-2697.
2.
Fig 2.

Fig 2. From: Estrogen Alone in Postmenopausal Women and Breast Cancer Detection by Means of Mammography and Breast Biopsy.

Random assignment in the Women's Health Initiative (WHI) dietary modification (DM) and calcium/vitamin D (CaD) clinical trials by random assignment group in the WHI conjugated equine estrogen (CEE) clinical trial. As women could participate in all three trials and could be randomly assigned to an intervention (I) or control (C) group in the DM trial or in the active drug (CaD) or placebo (CaD Plc) groups in the CaD trial, a total of nine categories are described.

Rowan T. Chlebowski, et al. J Clin Oncol. 2010 June 1;28(16):2690-2697.
3.
Fig 3.

Fig 3. From: Estrogen Alone in Postmenopausal Women and Breast Cancer Detection by Means of Mammography and Breast Biopsy.

Initial report of a mammogram with (A) recommendation for short-interval follow-up or suggestive or highly suggestive of cancer and (B) initial report of breast biopsy for participants by year on study and random assignment group. Women in the conjugated equine estrogen (CEE) group had about a 4% greater risk of a mammogram with recommendation for short-interval follow-up after 1 year and 9% greater risk after 5 years of use (P < .001). Women in the CEE group had about a 2% greater risk of having a biopsy after 5 years of use (P = .004). Standard error (SE) bars were plotted at each data point but may not be visible because of their small sizes relative to the data point.

Rowan T. Chlebowski, et al. J Clin Oncol. 2010 June 1;28(16):2690-2697.
4.
Fig 4.

Fig 4. From: Estrogen Alone in Postmenopausal Women and Breast Cancer Detection by Means of Mammography and Breast Biopsy.

Diagnostic performance of mammograms by study period and randomization group. (A) Intent-to-treat analysis conducted using receiver operating curves (ROC) and nested area under the curve (AUC) statistics. For placebo-group women, the ROC AUCs were 0.89, 0.85, and 0.92 for mammograms performed in years 1 to 2, 3 to 4, and ≥ 5, respectively. For women in the conjugated equine estrogen (CEE) group, the ROC AUCs were 0.85 (P = .027), 0.88 (P = .792), and 0.91 (P = .580) for mammograms performed in year 1 to 2, 3 to 4, and ≥ 5, respectively. P values compared abnormal versus normal mammograms for hormone-group versus placebo-group women. (B) Sensitivity analysis, excluding mammogram findings 6 months after a woman became nonadherent to study medication use. In these analyses, mammogram diagnostic performance for women in the CEE group was not significantly different from those in the placebo group for any period examined (P = .38, .49, and .06 in years 1 to 2, 3 to 4, and ≥ 5, respectively).

Rowan T. Chlebowski, et al. J Clin Oncol. 2010 June 1;28(16):2690-2697.

Supplemental Content

Recent activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...
Write to the Help Desk